OR-GUROBI-OPTIMIZATION
Gurobi Optimization, LLC, creator of the world’s fastest mathematical optimization solver, has launched a new program to help independent software vendors (ISVs) tackle customers’ increasingly complex business challenges and keep up with ever-evolving customer needs.
While 85% of Fortune 500 companies use mathematical optimization, smaller startups and scaleups in the tech world are catching on to the value an industry-leading solver like Gurobi can bring to their software solutions. In fact, 70% of top global tech companies now use Gurobi.
Gurobi wants to be more than just a supplier to the ISVs that utilize its mathematical optimization technology; it wants to be a partner. That is the motivation behind the new Gurobi Partner Accelerator Program.
The 36-month program aims to create joint value between Gurobi and solution providers by setting and achieving shared business, product, and revenue goals.
“It’s not just a supplier relationship. We see it as a partnership. We want to support these companies and go hand-in-hand with them. If they grow, we grow together,” explained Jan Schwarzkopf, Gurobi Account Manager - Europe Ecosystem.
The Gurobi Partner Accelerator Program
Gurobi is offering a partnership with companies in the final stages of developing a software solution that utilizes its optimization technology. Companies will receive ongoing technical support, which is a critical asset in these final development stages.
In addition to technical support, partner companies will receive business and marketing support to accelerate their product’s time to market and maximize sales once launched.
This program is not just for companies in the development stage, though. ISVs that utilize Gurobi for products already on the market will also be eligible. The program’s ongoing technical and business support is essential for any company that wants to enhance its product to stay ahead in the highly competitive software market.
Benefits of the Program
By participating in the program, ISVs will receive the following:
- Easy Access to Gurobi’s Technology - Solution partners will receive access to Gurobi’s best-in-class technology, including a product license based on their business needs.
- Ongoing Sales and Marketing Support - The program includes guidance on sales and marketing strategies. Gurobi will work hand-in-hand with partners to advise on the best way to market their product and maximize sales once launched.
- Quarterly Engagement for Business Strategy - Gurobi will meet at least quarterly with solution partners to assist with high-level business strategy. Partners will get expert guidance on formulating and executing business goals.
Who Should Consider This Program?
The Gurobi Partner Accelerator Program is not limited to ISVs currently using Gurobi’s technology for their software solutions. Companies using an open-source solver or competitive commercial solver are also encouraged to consider the program.
For those using either an open-source or commercial solver, Gurobi poses the following questions:
- Are you or your end customers satisfied with the current performance of your software application?
- Does your relationship with your current optimization technology supplier support your business growth?
If the answer to one or both of these questions is no, the Gurobi Partner Accelerator Program might be the solution.
The software industry is getting more competitive every year, and ISVs need to ensure their solutions use every advantage available. The Gurobi Partner Accelerator Program is an excellent opportunity to access leading optimization solver technology, as well as hands-on support from experts who want their partners to succeed with optimization.
To learn more about the program, please visit https://www.gurobi.com/gurobi-alliance/gurobi-partner-accelerator-program/.
About Gurobi Optimization
With Gurobi’s decision intelligence technology, you can make optimal business decisions in seconds. From workforce scheduling, portfolio management, and marketing optimization, to supply chain design, and everything in between, Gurobi identifies your optimal solution, out of trillions of possibilities.
As the leader in decision intelligence, Gurobi delivers easy-to-integrate, full-featured software and best-in-class support, with an industry-leading 98.5% customer satisfaction rating.
Founded in 2008, Gurobi has operations across the Americas, Europe, and Asia. Over 2,500 global customers across 40+ industries run on Gurobi, including SAP, Air France, and the National Football League, as well as half of the Fortune 10 and 70% of top global tech companies. For more information, please visit https://www.gurobi.com/ or call +1 713 871 9341.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220901005558/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67th American Society of Hematology (ASH) Annual Meeting6.12.2025 15:30:00 CET | Press release
Results from Phase 2a IMPRSSION study demonstrate sapablursen significantly reduced phlebotomy rate, controlled hematocrit and increased serum hepcidin Sapablursen was generally safe and well tolerated Results support further development of sapablursen in a Phase 3 study Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which On
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 15:30:00 CET | Press release
52-Week Results from the Phase 3 VERIFY Study of Rusfertide Demonstrated Sustained Hematocrit Control and Response, Defined by Absence of Phlebotomy Eligibility, with No New Safety SignalsThese Data Build on Positive 32-Week Primary Analysis from VERIFY, Which Met its Primary Efficacy Endpoint and All Four Key Secondary EndpointsPatients Crossing Over from Placebo to Rusfertide at 32 Weeks Achieved a Similar Response Rate to Those Initially Randomized to Rusfertide, with 77.9% Achieving Absence of Phlebotomy Eligibility Between Weeks 40-52Four-Year Results from the Combined REVIVE and Long-Term Extension THRIVE Study Demonstrated a 13-Fold Reduction in Annual Rate of Phlebotomies from Baseline Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society
Vertex Presents New Data on CASGEVY®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions6.12.2025 13:01:00 CET | Press release
- Data from pivotal studies of CASGEVY in children ages 5-11 years with severe sickle cell disease or transfusion-dependent beta thalassemia demonstrates the transformative potential of the therapy in younger patients -- Efficacy and safety data in children 5-11 years are consistent with the durable and positive benefit/risk profile established from clinical studies in patients 12 years of age and older -- Vertex expects to initiate global regulatory submissions for CASGEVY in children 5-11 years in 1H 2026 - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data from multiple studies demonstrating the clinical benefits of CASGEVY® (exagamglogene autotemcel) in people ages 5 years and older living with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT). The results, including the first presentation of clinical data from pivotal studies in children ages 5-11 years, and longer-term data from the pivotal studies of people with severe SCD and
Leading Global Scientists Gather at Tengchong Scientists Forum to Explore Innovative Pathways in Frontier Technologies6.12.2025 12:31:00 CET | Press release
The 2025 Tengchong Scientists Forum opened on Saturday in southwest China’s Yunnan Province, convening leading scientists and academic figures to examine innovation across frontier fields including artificial intelligence, biodiversity and quantum technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251205499197/en/ Opening ceremony of Tengchong Scientists Forum on 6th December, 2025 Notable participants include Nobel Physics laureate Konstantin Novoselov, Fields Medalist Efim Zelmanov and Turing Award winner Andrew Chi-Chih Yao, who join 127 academicians, 77 university presidents from China and abroad, over 400 scholars and more than 600 entrepreneurs and financiers. The gathering aims to deepen collaboration between cutting-edge research and industrial development. Under the theme “Science · AI changing the World,” the forum features ten sub-forums, academic sessions and thematic events supporting major cooperation p
Lattice Wins 2025 Global Semiconductor Alliance Award6.12.2025 00:49:00 CET | Press release
‒ Named Most Respected Public Semiconductor Company Achieving $100 Million to $500 Million in Annual Sales ‒ Lattice Semiconductor (NASDAQ: LSCC), the low power programmable leader, today announced that it was selected as ‘Most Respected Public Semiconductor Company’ at the 2025 Global Semiconductor Alliance (GSA) Awards. The GSA awards recognize companies that have demonstrated excellence through their success, vision, strategy, and future opportunities in the industry as determined by votes from GSA members. “We are honored to be recognized by the Global Semiconductor Alliance and our peers as one of 2025’s most respected public semiconductor companies. This recognition reflects the dedication of the Lattice team and the trust of our customers, partners, suppliers, and investors. Looking ahead, we remain laser-focused on driving innovation and strengthening our role as the trusted low power programmable leader for semiconductor and system solutions,” said Ford Tamer, Chief Executive
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom